Creative Medical Technology Holdings (CELZ) Total Current Liabilities (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Total Current Liabilities of $307649.0 for Q1 2026, up 7.42% year-over-year from $286387.0 in Q1 2025, and up 7.99% quarter-over-quarter from $284880.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Total Current Liabilities (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Total Current Liabilities for 17 consecutive years, with $307649.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 7.42% year-over-year to $307649.0; the TTM figure through Mar 2026 stood at $307649.0 (up 7.42% YoY), while the FY2025 annual figure was $284880.0, down 13.05% from the prior year.
- Total Current Liabilities climbed to $307649.0 in Q1 2026 per CELZ's latest filing, from $284880.0 in the prior quarter.
- Across five years, Total Current Liabilities topped out at $3.3 million in Q4 2022 and bottomed at $261353.0 in Q3 2025.
- Historically, Total Current Liabilities has averaged $525324.2 across 5 years, with a median of $376272.0 in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 216.21% — and 2023, when it plunged 88.82%.
- Creative Medical Technology Holdings' Total Current Liabilities stood at $3.3 million in 2022, then slumped by 88.82% to $371394.0 in 2023, then retreated by 11.78% to $327644.0 in 2024, then decreased by 13.05% to $284880.0 in 2025, then increased by 7.99% to $307649.0 in 2026.
- Business Quant data shows CELZ's Total Current Liabilities at $307649.0 in Q1 2026, $284880.0 in Q4 2025, and $261353.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 698,595.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 698,595.00 |
| Mar 31, 2026 | 307,649.00 |
| Dec 31, 2025 | 284,880.00 |
| Sep 30, 2025 | 261,353.00 |
| Jun 30, 2025 | 277,644.00 |
| Mar 31, 2025 | 286,387.00 |
| Dec 31, 2024 | 327,644.00 |
| Sep 30, 2024 | 330,908.00 |
| Jun 30, 2024 | 376,272.00 |
| Mar 31, 2024 | 390,959.00 |
| Dec 31, 2023 | 371,394.00 |
| Sep 30, 2023 | 421,159.00 |
| Jun 30, 2023 | 398,527.00 |
| Mar 31, 2023 | 407,536.00 |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 396,957.00 |
| Jun 30, 2022 | 389,795.00 |
| Mar 31, 2022 | 379,795.00 |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 3.50 Mn |